GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

This is a Phase Ib/II, open-label, multi-cohort, multi-center study to evaluate the safety, tolerability, and preliminary anti-tumor activity of GB268, a biological product, as monotherapy or in combination with other therapies in patients with locally advanced unresectable or metastatic breast cancer.

NCT Number	NCT07738341
Lead Sponsor	Eddingpharm (Zhuhai) Co., Ltd.
Conditions	Breast Cancer (Locally Advanced or Metastatic)
Enrollment	270 participants
Start Date	2026-08-01
Primary Completion	2029-08-01 (estimated)
Study Completion	2030-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-31